Company Analysis
Sign in

Structure Therapeutics Inc. (GPCR)

Nasdaq: GPCR · Pharmaceutical Preparations · South San Francisco, CA · filing with the SEC since 2021
Full chart Alerts Compare
Grade5.8
◀ Past 4.0● Present 7.4▶ Future 5.6
7 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

12 patents granted to the 8 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Structure Therapeutics Inc.’s names, not what it holds today.

Patents granted
12
12 utility, 1976 to Dec 31, 2025
Granted in 2025
4
Against 5 in 2024 and 1 in 2023
Applications published
37
12 of them in 2025
Names they are printed under
8
a subsidiary
By yearGrantedApplications published
'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals8
Organic fine chemistry4
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name8 counted
Gasherbrum Bio, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
25 published
Gasherbrum Bio, Inc. a subsidiary
US, as the owner printed on each patent
6 granted
0 published
Annapurna Bio, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
5 published
ACONCAGUA BIO, INC. a subsidiary
named as the applicant on its applications, in US
0 granted
3 published
Annapurna Bio, Inc. a subsidiary
US, as the owner printed on each patent
3 granted
0 published
Lhotse Bio, Inc. a subsidiary
US, as the owner printed on each patent
2 granted
1 published
Lhotse Bio, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
3 published
Aconcagua Bio, Inc. a subsidiary
US, as the owner printed on each patent
1 granted
0 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 2, 202512,486,269Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activityPharmaceuticalsAconcagua Bio, Inc.
Sep 30, 202512,428,375Compounds and compositions for treating conditions associated with LPA receptor activityOrganic fine chemistryLhotse Bio, Inc.
May 6, 202512,291,529Heterocyclic GLP-1 agonistsOrganic fine chemistryGasherbrum Bio, Inc.
Feb 11, 202512,221,442Heterocyclic GLP-1 agonistsPharmaceuticalsGasherbrum Bio, Inc.
Apr 2, 202411,944,622Compounds and compositions for treating conditions associated with APJ receptor activityPharmaceuticalsAnnapurna Bio, Inc.
Mar 12, 202411,926,643Heterocyclic GLP-1 agonistsPharmaceuticalsGasherbrum Bio, Inc.
Mar 12, 202411,926,626Heterocyclic GLP-1 agonistsPharmaceuticalsGasherbrum Bio, Inc.
Feb 13, 202411,897,851Heterocyclic GLP-1 agonistsPharmaceuticalsGasherbrum Bio, Inc.
Jan 30, 202411,884,627Compounds and compositions for treating conditions associated with LPA receptor activityOrganic fine chemistryLhotse Bio, Inc.
Aug 15, 202311,724,997Compounds and compositions for treating conditions associated with APJ receptor activityOrganic fine chemistryAnnapurna Bio, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Aug 14, 20252025/0257067COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH CALCITONIN RECEPTOR AND/OR AMYLIN RECEPTOR ACTIVITYPharmaceuticalsACONCAGUA BIO, INC. · patent 12,486,269 granted from it
Aug 7, 20252025/0250269HETEROCYCLIC GLP-1 AGONISTSOrganic fine chemistryGasherbrum Bio, Inc.
Jul 3, 20252025/0214999HETEROCYCLIC GLP-1 AGONISTSPharmaceuticalsGasherbrum Bio, Inc.
Jun 26, 20252025/02067575,8-DIHYDRO-1,7-NAPHTHYRIDINE DERIVATIVES AS GLP-1 AGONISTS FOR THE TREATMENT OF DIABETESPharmaceuticalsGasherbrum Bio, Inc.
Jun 12, 20252025/0188103HETEROCYCLIC GLP-1 AGONISTSOrganic fine chemistryGasherbrum Bio, Inc.
Jun 5, 20252025/0177362HETEROCYCLIC GLP-1 AGONISTSOrganic fine chemistryGasherbrum Bio, Inc.
May 8, 20252025/0145596HETEROCYCLIC GLP-1 AGONISTSPharmaceuticalsGasherbrum Bio, Inc.
Apr 10, 20252025/0115606HETEROCYCLIC GLP-1 AGONISTSPharmaceuticalsGasherbrum Bio, Inc.
Apr 3, 20252025/0109148HETEROCYCLIC GLP-1 AGONISTSOrganic fine chemistryGasherbrum Bio, Inc.
Feb 13, 20252025/0051355COMPOUNDS, COMPOSITIONS, AND METHODSPharmaceuticalsACONCAGUA BIO, INC.
What it applied for, 2024 to 2025: Pharmaceuticals 13 · Organic fine chemistry 10.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton GPCR · research, not advice